AVADEL PHARMACEUTICALS (AVDL)

Avadel Pharmaceuticals to Present at the 23rd Annual Needham Healthcare Conference

DUBLIN, Ireland, April 01, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming...

Avadel Pharmaceuticals to Present at Upcoming Investor Conferences

DUBLIN, Ireland, March 05, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming...

Avadel Pharmaceuticals Issues Statement On Patent Litigation

DUBLIN, Ireland, March 04, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), today issued a statement in response to a jury ruling from...

Avadel Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results

-- Generated $19.5 million in fourth quarter and $28.0 million of full year 2023 net revenue from sales of LUMRYZ™ -- -- As of January 31st,...

Avadel Pharmaceuticals (AVDL) Shares Cross Below 200 DMA

First Week of September 20th Options Trading For Avadel Pharmaceuticals (AVDL)

Avadel Pharmaceuticals estimates Q4 net product revenue of ~$19M (NASDAQ:AVDL)

Avadel Pharmaceuticals reports Q4 net product revenue of ~$19M and projects ~$28M for 2023.

Avadel Pharmaceuticals (AVDL) Shares Cross Above 200 DMA

UBS lowers Jazz to neutral, cites potential competition from Avadel drug (NASDAQ:JAZZ)

UBS lowered its rating of Jazz Pharmaceuticals (JAZZ) to neutral, citing potential competition from Avadel's (AVDL) Lumryz sleep drug. Read more here.

Avadel Pharmaceuticals Breaks Above 200-Day Moving Average - Bullish for AVDL

Avadel Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2023 Financial Results

-- $7.0 million in third quarter LUMRYZ™ net revenue from U.S. commercial launch -- -- Generated robust demand for LUMRYZ with greater than 1,000...

Avadel Pharmaceuticals Announces Data Supporting Clinical Profile for LUMRYZ™ (sodium oxybate) for extended-release oral suspension (CIII) at World Sleep 2023

– 17 abstracts accepted, including new and encore data emphasizing clinical benefit and patient preference for a once-at-bedtime narcolepsy treatment...

Interesting AVDL Put And Call Options For March 2024

Avadel Pharmaceuticals (AVDL) Shares Cross Above 200 DMA

Avadel Pharmaceuticals Becomes Oversold (AVDL)

Avadel Pharmaceuticals to Present at the Jefferies Biotech CNS/Neuro Summit

DUBLIN, Ireland, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming...

Avadel Pharmaceuticals is Now Oversold (AVDL)

Avadel Pharmaceuticals to Present at Upcoming Investor Conferences

DUBLIN, Ireland, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming...

Avadel Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2023 Financial Results

-- Successfully commenced U.S. commercial launch of LUMRYZ™-- -- Received final FDA approval for LUMRYZ with orphan drug exclusivity granted through...

Avadel Pharmaceuticals to Provide a Corporate Update and Report Second Quarter Financial Results on August 9

DUBLIN, Ireland, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming...

Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

DUBLIN, Ireland, July 20, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform...

Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

DUBLIN, Ireland, July 06, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform...